MUC5AC and colitis: Previous studies have shown that in DSS-treated mice, MUC2 and MUC5AC levels were reduced, which has been confirmed by previous research that DSS-treated mice had lower MUC2 and MUC5AC levels, which resulted in spontaneous colitis development [55,56].